AI Terminal
ARECOR THERAPEUTICS PLC
Board/Management Information • Apr 23, 2024
7494_rns_2024-04-23_00e026a4-30c7-43ea-ae41-3bcc5ce38aa9.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5889L
Arecor Therapeutics PLC
23 April 2024
Arecor Therapeutics plc
("Arecor" or the "Company")
BOARD CHANGE
ARECOR ANNOUNCES SUSAN LOWTHER TO STEP DOWN AS CHIEF FINANCIAL OFFICER
Cambridge, UK, 23 April 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announced that Susan Lowther has decided to step down from her role as Chief Financial Officer, Company Secretary and as a Board Director, to pursue new opportunities.
A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover.
Sarah Howell, Chief Executive Officer of Arecor, said: "On behalf of the Board and all at Arecor, I want to thank Susan for her contributions over the past five years, in our transition to a public company and growth as a business. We wish her every success in her future plans."
Susan Lowther, Chief Financial Officer of Arecor, said: "I am proud to have been Arecor's first Chief Financial Officer and of our achievements as a business, and believe the Company is well placed for further growth. I will watch the future progress with interest."
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Panmure Gordon (UK) Limited (NOMAD and Broker) | |
| Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
| WG Partners LLP (Financial Advisor) | |
| Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
| ICR Consilium | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAUUAKRSBUSUAR